Anti-hyperplastic effects of Acmella oleracea flower and leaf extracts in prostate cell lines and in spontaneously hypertensive rats
Abstract
Benign prostatic hyperplasia (BPH) is a highly prevalent age-associated disorder and a leading cause of lower urinary tract symptoms in men worldwide. Given the limitations of current therapies, there is increasing interest in phytotherapeutic compounds as sources of biologically active agents. Acmella oleracea, a medicinal plant rich in the alkamide spilanthol, has been traditionally associated with urogenital effects; however, the biological impact of distinct plant organs on prostate hyperplasia remains poorly defined. In this study, we investigated the effects of flower (A.Fl) and leaf (A.Le) extracts of A. oleracea using human prostate cell lines (RWPE-1 and PC-3) and a spontaneously hypertensive rat (SHR) model of BPH. In vitro analyses included cell viability assays and immunofluorescence for androgen receptor (AR), estrogen receptor alpha (ERα), and proliferating cell nuclear antigen (PCNA). In vivo, SHR were treated orally with A.Fl or A.Le (100 mg/kg/day for 21 days), followed by morphological, immunohistochemical, ultrastructural, and oxidative stress analyses of the ventral prostate. A.Fl displayed lower cytotoxicity than A.Le in both prostate cell lines and preferentially increased ERα immunoreactivity, whereas A.Le more strongly modulated AR without affecting cell proliferation. In SHR, both extracts attenuated prostatic hyperplasia, although A.Fl produced a more pronounced reduction in epithelial proliferation and stromal remodeling. These effects occurred…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.